2-methyl-4-propoxy-1-nitrobenzene | 52177-07-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-4-propoxy-1-nitrobenzene
• 英文别名: (3-methyl-4-nitro-phenyl)-propyl ether；(3-Methyl-4-nitro-phenyl)-propyl-aether；6-Nitro-3-n-propoxytoluene；2-Methyl-1-nitro-4-propoxybenzene
• CAS: 52177-07-8
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: SPAWIUFDIDDJDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-4-propoxy-1-nitrobenzene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 4.0h， 以85%的产率得到2-methyl-4-propoxyaniline
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Indolyl-Pyridinyl-Propenones Having Either Methuosis or Microtubule Disruption Activity

  摘要：

  Methuosis is a form of nonapoptotic cell death characterized by an accumulation of macropinosome-derived vacuoles with eventual loss of membrane integrity. Small molecules inducing methuosis could offer significant advantages compared to more traditional anticancer drug therapies that typically rely on apoptosis. Herein we further define the effects of chemical substitutions at the 2- and 5-indolyl positions on our lead compound 3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propene-1-one (MOMIPP). We have identified a number of compounds that induce methuosis at similar potencies, including an interesting analogue having a hydroxypropyl substituent at the 2-position. In addition, we have discovered that certain substitutions on the 2-indolyl position redirect the mode of cytotoxicity from methuosis to microtubule disruption. This switch in activity is associated with an increase in potency as large as 2 orders of magnitude. These compounds appear to represent a new class of potent microtubule-active anticancer agents.

  DOI：

  10.1021/jm501997q
• 作为产物：
  描述：

  4-硝基间甲苯酚 、 溴丙烷 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 反应 18.08h， 以99%的产率得到2-methyl-4-propoxy-1-nitrobenzene
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Indolyl-Pyridinyl-Propenones Having Either Methuosis or Microtubule Disruption Activity

  摘要：

  Methuosis is a form of nonapoptotic cell death characterized by an accumulation of macropinosome-derived vacuoles with eventual loss of membrane integrity. Small molecules inducing methuosis could offer significant advantages compared to more traditional anticancer drug therapies that typically rely on apoptosis. Herein we further define the effects of chemical substitutions at the 2- and 5-indolyl positions on our lead compound 3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propene-1-one (MOMIPP). We have identified a number of compounds that induce methuosis at similar potencies, including an interesting analogue having a hydroxypropyl substituent at the 2-position. In addition, we have discovered that certain substitutions on the 2-indolyl position redirect the mode of cytotoxicity from methuosis to microtubule disruption. This switch in activity is associated with an increase in potency as large as 2 orders of magnitude. These compounds appear to represent a new class of potent microtubule-active anticancer agents.

  DOI：

  10.1021/jm501997q

文献信息

• Über lokalanästhetisch wirksame Substitutionsderivate des Diäthylamino-acyl-anilids
  作者：J. Büchi、G. Lauener、L. Ragaz、H. Böniger、R. Lieberherr

  DOI：10.1002/hlca.19510340131

  日期：——

  hergestellt und auf ihre pharmakologischen Wirkungen untersucht. Die hier beschriebenen Diäthylamino-acylaminophenol-alkyläther und Diäthylamino-acetylamino-toluol-alkyläther zeigen ähnliche Zusammenhänge zwischen Konstitution und Wirkung, wie sie schon bei andern Stoffgruppen beobachtet worden sind. Es wurde zudem auf den eigenartigen Einfluss der Einführung von Methylgruppen in den Phenolkern des p-(Diä

  Es wurden verschiedene同系物Reihen vonXylocain-ähnlichenLokalanästhetikahergestellt和auf i pharmakologischen Wirkungen untersucht。乙二氨基氨基-乙酰氨基苯酚-烷基醚和二乙氨基-乙酰氨基-甲苯基-烷基醚的合成和Wirkung的二元氨基-乙酰氨基-乙酰氨基-苯酚烷基酯和Wirkung的二氨基氨基-乙酰氨基-乙酰氨基酚烷基酯。在对苯二甲酰二乙酰氨基乙酰氨基苯酚烷基酚的合成中使用了甲基丙烯酸丁酯（Einfluss derEinführungvonEinführungvon Methylgruppen）。Dabei konnte beim二氨基氨基乙酰氨基-二甲苯醇-烷基酯，D Kombination der Strukturen des Xylocains和des Pacetacetins，Eine
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• Novel indazole derivatives
  申请人：Hagihara Masahiko

  公开号：US20070129404A1

  公开（公告）日：2007-06-07

  An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R 1 and R 2 are H or alkyl; R 3 and R 4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R 5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.

  本发明的目的是创建一种新的吲唑衍生物作为药物，并找到该衍生物的新的药理作用。本发明的化合物由公式[I]表示，并具有出色的Rho激酶抑制作用。在公式中，环X是苯环或吡啶环；R1和R2是H或烷基；R3和R4是卤素，H，OH，烷氧基，烯氧基，炔氧基，环烷氧基，环烯氧基，芳氧基，烷基，烯基，炔基，环烷基，环烯基，芳基，羧基，烷基羰基等；而R5是卤素原子，H，OH，烷氧基，芳氧基，烷基或芳基。每个基团都可以被取代。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• AROMATIC COMPOUND
  申请人：FUKUSHIMA Tae

  公开号：US20120238750A1

  公开（公告）日：2012-09-20

  The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，而R6表示具有1至4个氮原子、氧原子或硫原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基链或类似物; A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，而R4表示咪唑基较低的烷基链或类似物。